

Zydus receives final approval from the USFDA for Nystatin Ointment USP and Omeprazole and Sodium Bicarbonate Capsules

Ahmedabad, 28 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Nystatin Ointment USP, 100,000 units per gram. It is used as an adjunct to treat fungal skin infections and will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group also received the final approval to market Omeprazole and Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg. It is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
